The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Merighi, S., Gessi, S., Varani, K., Simioni, C., Fazzi, D., Mirandola, P., & Borea, P. A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01673.x · Cited by 51
RetractedInternational Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationAdverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Ferguson, S. S. G. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01478-9 · Cited by 1,826
Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., LE Fur, G., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,749
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Beta-caryophyllene is a dietary cannabinoid.
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., & Zimmer, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803601105 · Cited by 906
Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 869
Self-citationRegulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
CB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Self-citationA unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707936104 · Cited by 597
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544
Peripheral cannabinoid receptor, CB2, regulates bone mass
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504187103 · Cited by 536
Pharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Functional Selectivity and Biased Receptor Signaling
Kenakin, T. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173948 · Cited by 505
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 484
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03380.x · Cited by 482
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Molina-Holgado, E., Vela, J. M., Arévalo-Martı́n, A., Almazán, G., Molina-Holgado, F., Borrell, J., & Guaza, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09742.2002 · Cited by 419
CB2 cannabinoid receptor-mediated peripheral antinociception
Malan, P. T., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T., Porreca, F., & Makriyannis, A. (2001) · Pain · doi:10.1016/s0304-3959(01)00321-9 · Cited by 391
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 377
Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., & Waku, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.605 · Cited by 371
Biased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363
Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T., & Kaminski, N. E. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8034 · Cited by 358
G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins
Ferguson, S. S. G., Barak, L. S., Zhang, J., & Caron, M. G. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-74-10-1095 · Cited by 330
Expanding roles for β-arrestins as scaffolds and adapters in GPCR signaling and trafficking
Miller, W. E., & Lefkowitz, R. J. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00190-3 · Cited by 322
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins
Ferguson, S., Barak, L. S., Zhang, J., & Caron, M. G. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y96-124 · Cited by 294
Bouaboula, M., Poinot‐Chazel, C., Marchand, J., Canat, X., Bourrié, B., Rinaldi‐Carmona, M., Calandra, B., Le Fur, G., & Casellas, P. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0704p.x · Cited by 286
Signaling from G-Protein-coupled Receptors to Mitogen-activated Protein (MAP)-Kinase Cascades
Lopez-Ilasaca, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00059-8 · Cited by 272
Wright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., & Winter, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.009 · Cited by 251
Liu, Q. ‐., Pan, C. ‐., Hishimoto, A., Li, C. ‐., Xi, Z. ‐., Llorente‐Berzal, A., Viveros, M. ‐., Ishiguro, H., Arinami, T., Onaivi, E. S., et al. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2009.00498.x · Cited by 246
Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury
Batkai, S., Osei‐Hyiaman, D., Pan, H., El‐Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., Harvey‐White, J., Jafri, A., Haskó, G., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7451com · Cited by 246
Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain
Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., Casadó, V., Lanciego, J. L., Franco, R., Lluis, C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335273 · Cited by 238
Franklin, A., Parmentier-Batteur, S., Walter, L., Greenberg, D. A., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-21-07767.2003 · Cited by 231
Rozenfeld, R., & Devi, L. A. (2007) · The FASEB Journal · doi:10.1096/fj.06-7793com · Cited by 220
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Shoemaker, J. L., Seely, K. A., Reed, R. L., Crow, J. P., & Prather, P. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04346.x · Cited by 207
Deng, L., Guindon, J., Cornett, B. L., Makriyannis, A., Mackie, K., & Hohmann, A. G. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.009 · Cited by 204
Self-citationEmerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Izzo, A. A., & Camilleri, M. (2008) · Gut · doi:10.1136/gut.2008.148791 · Cited by 199
Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M., & Metters, K. M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10254-x · Cited by 191
Cloning and molecular characterization of the rat CB2 cannabinoid receptor
Brown, S. M., Wager-Miller, J., & Mackie, K. (2002) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(02)00341-x · Cited by 190
Self-citationZhang, M., Martin, B. R., Adler, M. W., Razdan, R. K., Jallo, J. I., & Tuma, R. F. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600447 · Cited by 164
McAllister, S. D., Griffin, G., Satin, L. S., & Abood, M. E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35147-x · Cited by 160
Atwood, B. K., Wager‐Miller, J., Haskins, C. P., Straiker, A. J., & Mackie, K. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074013 · Cited by 160
Self-citationTherapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
Han, S., Thatte, J., Buzard, D. J., & Jones, R. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005626 · Cited by 157
Kim, K., Moore, D. H., Makriyannis, A., & Abood, M. E. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.025 · Cited by 153
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy
Barutta, F., Piscitelli, F., Pinach, S., Bruno, G., Gambino, R., Rastaldi, M. P., Salvidio, G., Marzo, V. D., Perin, P. C., & Gruden, G. (2011) · Diabetes · doi:10.2337/db10-1809 · Cited by 145
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139 · cited 1×
“tion (Maresz et al., 2005; Hsieh et al., 2011).”
Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors
Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R., & Prather, P. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089474 · Cited by 133
Kaminski, N. E., Koh, W. S., Yang, K. H., Lee, M., & Kessler, F. K. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90588-6 · Cited by 132
Ostenfeld, T., Price, J. A., Albanese, M., Bullman, J., Guillard, F., Meyer, I., Leeson, R., Costantin, C., Ziviani, L., Nocini, P. F., et al. (2011) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e318219799a · Cited by 126
Yao, B. B., Mukherjee, S., Fan, Y., Garrison, T. R., Daza, A. V., Grayson, G. K., Hooker, B. A., Dart, M. J., Sullivan, J. P., & Meyer, M. D. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706838 · Cited by 120
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
Gewandter, J. S., Dworkin, R. H., Turk, D. C., McDermott, M. P., Baron, R., Gastonguay, M. R., Gilron, I., Katz, N. P., Mehta, C. R., Raja, S. N., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.025 · Cited by 117
CB2 receptors as new therapeutic targets for liver diseases
Lotersztajn, S., Teixeira-Clerc, F., Julien, B., Deveaux, V., Ichigotani, Y., Manin, S., Nhieu, J. T. V., Karsak, M., Zimmer, A., & Mallat, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707511 · Cited by 114
Whiteside, G. T., Gottshall, S. L., Boulet, J. M., Chaffer, S. M., Harrison, J., Pearson, M. S., Turchin, P. I., Mark, L., Garrison, A. E., & Valenzano, K. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.043 · Cited by 106
Herrera, B. M., Carracedo, A., Diez-Zaera, M., del Pulgar, T. G., Guzmán, M., & Velasco, G. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.009 · Cited by 104
The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization
Milligan, G. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.084780 · Cited by 103
Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Sagredo, O., Pazos, M. R., Valdeolivas, S., & Fernández‐Ruíz, J. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842278 · Cited by 101
Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors
Mukherjee, S., Adams, M., Whiteaker, K. L., Daza, A. V., Kage, K., Cassar, S. C., Meyer, M., & Yao, B. B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.058 · Cited by 99
Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
Roche, M., & Finn, D. P. (2010) · Pharmaceuticals · doi:10.3390/ph3082517 · Cited by 98
Bingham, B., JONES, P. G., Uveges, A. J., Kotnis, S., Lu, P., Smith, V. A., Sun, S., Resnick, L., Chlenov, M., He, Y., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707303 · Cited by 95
Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., & Damaj, M. I. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3117-6 · Cited by 89
The Phylogenetic Distribution and Evolutionary Origins of Endocannabinoid Signalling
Elphick, M. R., & Egertová, M. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_9 · Cited by 88
Grimsey, N. L., Goodfellow, C. E., Dragunow, M., & Glass, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.05.010 · Cited by 88
Ho, B. Y., Uezono, Y., Takada, S., Takase, I., & Izumi, F. (1999) · PubMed · Cited by 88
Receptor Heteromerization Expands the Repertoire of Cannabinoid Signaling in Rodent Neurons
Rozenfeld, R., Bushlin, I., Gomes, I., Tzavaras, N., Gupta, A., Neves, S. R., Battini, L., Gusella, G. L., Lachmann, A., Ma’ayan, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029239 · Cited by 87
p38 MAPK is involved in CB2 receptor‐induced apoptosis of human leukaemia cells
Herrera, B. M., Carracedo, A., Diez-Zaera, M., Guzmán, M., & Velasco, G. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.021 · Cited by 84
Cannabinoid receptors in acute and chronic complications of atherosclerosis
Mach, F., Montecucco, F., & Steffens, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707517 · Cited by 78
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain
Gutierrez, T., Crystal, J. D., Zvonok, A. M., Makriyannis, A., & Hohmann, A. G. (2011) · Pain · doi:10.1016/j.pain.2011.03.038 · Cited by 73
Schuehly, W., Paredes, J. M. V., Kleyer, J., Huefner, A., Anavi‐Goffer, S., Raduner, S., Altmann, K., & Gertsch, J. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.012 · Cited by 71
Herring, A. C., Koh, W. S., & Kaminski, N. E. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00630-8 · Cited by 70
Functionalization of β-Caryophyllene Generates Novel Polypharmacology in the Endocannabinoid System
Chicca, A., Caprioglio, D., Minassi, A., Petrucci, V., Appendino, G., Taglialatela‐Scafati, O., & Gertsch, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500177c · Cited by 67
Cannabinoid Type 2 Receptor as a Target for Chronic - Pain
Beltramo, M. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001785 · Cited by 62
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
Mallat, A., Teixeira-Clerc, F., Deveaux, V., & Lotersztajn, S. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.403 · Cited by 62
Characterizing Cannabinoid CB2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay
McGuinness, D., Malikzay, A., Visconti, R. J., Lin, K., BAYNE, M. L., Monsma, F. J., & Lunn, C. A. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108327329 · Cited by 60
Autocrine and Paracrine Regulation of Lymphocyte CB2 Receptor Expression by TGF-β
Gardner, B. K., Zu, L. X., Sharma, S. P., Liu, Q., Makriyannis, A., Tashkin, D. P., & Dubinett, S. M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6179 · Cited by 59
CB2 cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons
Atwood, B. K., Straiker, A. J., & Mackie, K. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.024 · Cited by 50
Self-citationEndocannabinoid Receptor Pharmacology
Yao, B. B., & Mackie, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_2 · Cited by 47
Self-citationSisay, S., Pryce, G., Jackson, S. J., Tanner, C., Ross, R. A., Michael, G. J., Selwood, D. L., Giovannoni, G., & Baker, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076907 · Cited by 46
Mastering tricyclic ring systems for desirable functional cannabinoid activity
Petrov, R. R., Knight, L., Chen, S.-R., Wager‐Miller, J., McDaniel, S. W., Astruc‐Diaz, F., Barth, F., Pan, H., Mackie, K., Cavasotto, C. N., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.038 · Cited by 45
Self-citationAn End to the Myth: There Is No Drug Development Pipeline
Baxter, K. K., Horn, E. J., Gal‐Edd, N., Zonno, K. D., O'Leary, J. C., Terry, P. F., & Terry, S. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3003505 · Cited by 45
Jun, L. S., Showalter, A. D., Ali, N., Dai, F. F., Ma, W., Coşkun, T., FICORILLI, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 37
Murataeva, N., Mackie, K., & Straiker, A. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.08.002 · Cited by 31
Self-citationDirect suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
Dittel, B. N. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707493 · Cited by 31
Different Classes of CB2 Ligands Potentially Useful in the Treatment of Pain
Murineddu, G., Deligia, F., Dore, A., Pinna, G., Asproni, B., & Pinna, G. A. (2013) · Recent Patents on CNS Drug Discovery · doi:10.2174/15748898112079990016 · Cited by 24
Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor
Han, S., Chen, J., & Chen, J. (2014) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557514666140428105753 · Cited by 23
Yamaori, S., Ishii, H., Chiba, K., Yamamoto, I., & Watanabe, K. (2013) · Toxicology · doi:10.1016/j.tox.2013.10.007 · Cited by 19
Cannabinoids and opioids share cAMP pathway in rat splenocytes
Massi, P., Vaccani, A., Rubino, T., & Parolaro, D. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.09.006 · Cited by 16
Evidence for a Cannabinoid Receptor in Immunomodulation by Cannabinoid Compounds
Kaminski, N. E. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2980-4_16 · Cited by 12
CB2 receptor as a potential target in age-related diseases
Kauppinen, A., Nevalainen, T., Hytti, M., Salminen, A., & Parkkari, T. (2014) · Cited by 4
Cited by
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 654
The endocannabinoid system in guarding against fear, anxiety and stress
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4036 · Cited by 506
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 375
Metadata
- Authors
- Dhopeshwarkar, A., & Mackie, K.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 86
- Issue
- 4
- Pages
- 430-437
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W2096703732
- Cited by
- 257
- References
- 102
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.